{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:26:44Z","timestamp":1787232404844,"version":"build-2736575974"},"reference-count":59,"publisher":"American Chemical Society (ACS)","issue":"15","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P01 GM109767"],"award-info":[{"award-number":["P01 GM109767"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The design, synthesis, and X-ray structural analysis of hybrid HIV-1 protease inhibitors (PIs) containing bis-tetrahydrofuran (bis-THF) in a pseudo-C2-symmetric dipeptide isostere are described. A series of PIs were synthesized by incorporating bis-THF of darunavir on either side of the Phe-Phe isostere of lopinavir in combination with hydrophobic amino acids on the opposite P2\/P2\u2032 position. Structure\u2013activity relationship studies indicated that the bis-THF moiety can be attached at either the P2 or P2\u2032 position without significantly affecting potency. However, the group on the opposite P2\/P2\u2032 position had a dramatic effect on potency depending on the size and shape of the side chain. Cocrystal structures of inhibitors with wild-type HIV-1 protease revealed that the bis-THF moiety retained similar interactions as observed in the darunavir\u2013protease complex regardless of the position on the Phe-Phe isostere. Analyses of cocrystal structures and molecular dynamics simulations provide insights into optimizing HIV-1 PIs containing bis-THF in non-sulfonamide dipeptide isosteres.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.0c00529","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T12:26:48Z","timestamp":1594902408000},"page":"8296-8313","source":"Crossref","is-referenced-by-count":8,"title":["Structural Analysis\nof Potent Hybrid HIV\u20111\nProtease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric\nDipeptide Isostere"],"prefix":"10.1021","volume":"63","author":[{"given":"Linah\nN.","family":"Rusere","sequence":"first","affiliation":[{"name":"University of Massachusetts Medical School , , , ,","place":["Worcester, Massachusetts, United States, 01605"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2720-6984","authenticated-orcid":true,"given":"Gordon J.","family":"Lockbaum","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School , , , ,","place":["Worcester, Massachusetts, United States, 01605"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Henes","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School , , , ,","place":["Worcester, Massachusetts, United States, 01605"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook-Kyung","family":"Lee","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ean","family":"Spielvogel","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desaboini Nageswara","family":"Rao","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School , , , ,","place":["Worcester, Massachusetts, United States, 01605"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klajdi","family":"Kosovrasti","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School , , , ,","place":["Worcester, Massachusetts, United States, 01605"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen A.","family":"Nalivaika","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School , , , ,","place":["Worcester, Massachusetts, United States, 01605"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Swanstrom","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5036-676X","authenticated-orcid":true,"given":"Nese","family":"Kurt Yilmaz","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School , , , ,","place":["Worcester, Massachusetts, United States, 01605"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2270-6613","authenticated-orcid":true,"given":"Celia A.","family":"Schiffer","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School , , , ,","place":["Worcester, Massachusetts, United States, 01605"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3491-791X","authenticated-orcid":true,"given":"Akbar","family":"Ali","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School , , , ,","place":["Worcester, Massachusetts, United States, 01605"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"2026082008091568200_cit1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and\nprospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"2026082008091568200_cit2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral\ndrugs for treatment and prevention of\nHIV infection in adults: 2018 recommendations of the international\nantiviral society-USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"2026082008091568200_cit3","unstructured":"Panel on Antiretroviral Guidelines\nfor Adults and Adolescents\n          . Guidelines\nfor the Use of Antiretroviral Agents in Adults and Adolescents with\nHIV; Department of Health and Human Services. Available at https:\/\/files.aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf. (Accessed February 15, 2020)."},{"key":"2026082008091568200_cit4","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/v2112509","article-title":"Molecular\nbasis for drug resistance in HIV-1 protease","volume":"2","author":"Ali","year":"2010","journal-title":"Viruses"},{"key":"2026082008091568200_cit5","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent progress\nin the development\nof HIV-1 protease inhibitors for the treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"key":"2026082008091568200_cit6","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1021\/jm049560p","article-title":"Discovery\nand selection of TMC114, a next generation HIV-1 protease inhibitor","volume":"48","author":"Surleraux","year":"2005","journal-title":"J. Med. Chem."},{"key":"2026082008091568200_cit7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1021\/ar7001232","article-title":"Design of HIV protease\ninhibitors targeting protein backbone: an effective strategy for combating\ndrug resistance","volume":"41","author":"Ghosh","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"2026082008091568200_cit8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmb.2004.02.052","article-title":"High resolution crystal structures of HIV-1 protease\nwith a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant\nclinical strains","volume":"338","author":"Tie","year":"2004","journal-title":"J. Mol. Biol."},{"key":"2026082008091568200_cit9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/cmdc.200600103","article-title":"Bis-tetrahydrofuran:\na privileged ligand for darunavir\nand a new generation of hiv protease inhibitors that combat drug resistance","volume":"1","author":"Ghosh","year":"2006","journal-title":"ChemMedChem"},{"key":"2026082008091568200_cit10","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1128\/AAC.00401-07","article-title":"In vitro antiviral activity of the\nnovel, tyrosyl-based human immunodeficiency\nvirus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination\nwith other antiretrovirals and against a panel of protease inhibitor-resistant\nHIV","volume":"51","author":"Hazen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026082008091568200_cit11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jmb.2006.07.073","article-title":"Suppression\nof HIV-1 protease inhibitor resistance by phosphonate-mediated solvent\nanchoring","volume":"363","author":"Cihlar","year":"2006","journal-title":"J. Mol. Biol."},{"key":"2026082008091568200_cit12","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1128\/AAC.00149-07","article-title":"In vitro\nantiviral\nactivity and cross-resistance profile of PL-100, a novel protease\ninhibitor of human immunodeficiency virus type 1","volume":"51","author":"Dandache","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026082008091568200_cit13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.bmcl.2012.10.095","article-title":"Design and synthesis\nof HIV-1 protease inhibitors for a long-acting injectable drug application","volume":"23","author":"Kesteleyn","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026082008091568200_cit14","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1021\/acsmedchemlett.7b00386","article-title":"Design\nand synthesis of piperazine sulfonamide cores leading to highly potent\nHIV-1 protease inhibitors","volume":"8","author":"Bungard","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"2026082008091568200_cit15","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.bmcl.2006.01.035","article-title":"Ultra-potent\nP1 modified arylsulfonamide HIV protease inhibitors: the discovery\nof GW0385","volume":"16","author":"Miller","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026082008091568200_cit16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1039\/c1md00147g","article-title":"Discovery\nof GS-8374,\na potent human immunodeficiency virus type 1 protease inhibitor with\na superior resistance profile","volume":"2","author":"He","year":"2011","journal-title":"MedChemComm"},{"key":"2026082008091568200_cit17","doi-asserted-by":"publisher","first-page":"14015","DOI":"10.1021\/jacs.8b07366","article-title":"Sub-picomolar inhibition of HIV-1\nprotease with a boronic acid","volume":"140","author":"Windsor","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"2026082008091568200_cit18","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.chembiol.2013.07.014","article-title":"Substrate envelope-designed potent\nHIV-1 protease inhibitors\nto avoid drug resistance","volume":"20","author":"Nalam","year":"2013","journal-title":"Chem. Biol."},{"key":"2026082008091568200_cit19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.28020","article-title":"A novel central nervous\nsystem-penetrating protease inhibitor overcomes human immunodeficiency\nvirus 1 resistance with unprecedented aM to pM potency","volume":"6","author":"Aoki","year":"2017","journal-title":"Elife"},{"key":"2026082008091568200_cit20","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1021\/acs.jmedchem.8b00298","article-title":"Design and synthesis\nof highly potent HIV-1 protease inhibitors containing tricyclic fused\nring systems as novel P2 ligands: structure-activity studies, biological\nand X-ray structural analysis","volume":"61","author":"Ghosh","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026082008091568200_cit21","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1021\/acs.jmedchem.7b00172","article-title":"Design and development of highly\npotent HIV-1 protease\ninhibitors with a crown-like oxotricyclic core as the P2-ligand to\ncombat multidrug-resistant HIV variants","volume":"60","author":"Ghosh","year":"2017","journal-title":"J.\nMed. Chem."},{"key":"2026082008091568200_cit22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1021\/jm1012787","article-title":"Design and synthesis of potent HIV-1\nprotease inhibitors incorporating hexahydrofuropyranol-derived high\naffinity P2 ligands: structure-activity studies and biological\nevaluation","volume":"54","author":"Ghosh","year":"2011","journal-title":"J. Med. Chem."},{"key":"2026082008091568200_cit23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.chembiol.2004.08.010","article-title":"Combating susceptibility\nto drug resistance: lessons from HIV-1 protease","volume":"11","author":"King","year":"2004","journal-title":"Chem. Biol."},{"key":"2026082008091568200_cit24","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1002\/anie.201509989","article-title":"Long-range\nelectrostatics-induced two-proton transfer captured by neutron crystallography\nin an enzyme catalytic site","volume":"55","author":"Gerlits","year":"2016","journal-title":"Angew. Chem., Int.\nEd."},{"key":"2026082008091568200_cit25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/bs.mie.2019.12.002","article-title":"Proton transfer\nand drug binding details revealed in neutron diffraction studies of\nwild-type and drug resistant HIV-1 protease","volume":"634","author":"Kovalevsky","year":"2020","journal-title":"Methods Enzymol."},{"key":"2026082008091568200_cit26","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1016\/j.bmcl.2003.08.043","article-title":"Synthesis and SAR\nstudies of potent HIV protease inhibitors\ncontaining novel dimethylphenoxyl acetates as P2 ligands","volume":"13","author":"Chen","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026082008091568200_cit27","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1016\/S0960-894X(96)00528-8","article-title":"Evaluation\nof furofuran as a P2 ligand for symmetry-based HIV protease inhibitors","volume":"6","author":"Chen","year":"1996","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026082008091568200_cit28","unstructured":"Cannizzaro, C. E.; Yang, Z.-Y.; Desai, M. C.; Mitchell, M. L.; Xu, L.; Swaminathan, S.; Chen, J.\nM.\n          Antiviral protease\ninhibitors. PCT Int. App. WO2008011117, 2008."},{"key":"2026082008091568200_cit29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jmb.2011.03.053","article-title":"Dynamics of preferential\nsubstrate\nrecognition in HIV-1 protease: redefining the substrate envelope","volume":"410","author":"O\u0308zen","year":"2011","journal-title":"J. Mol. Biol."},{"key":"2026082008091568200_cit30","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1021\/acs.jctc.6b01262","article-title":"Interdependence of inhibitor recognition\nin HIV-1 protease","volume":"13","author":"Paulsen","year":"2017","journal-title":"J. Chem. Theory Comput."},{"key":"2026082008091568200_cit31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1021\/op9802071","article-title":"Reduction of an enaminone: synthesis of the diamino\nalcohol core of ritonavir","volume":"3","author":"Haight","year":"1999","journal-title":"Org. Process Res.\nDev."},{"key":"2026082008091568200_cit32","doi-asserted-by":"publisher","first-page":"14137","DOI":"10.1021\/ja105044s","article-title":"Ligand-accelerated\nC-H activation\nreactions: evidence for a switch of mechanism","volume":"132","author":"Engle","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"2026082008091568200_cit33","doi-asserted-by":"publisher","first-page":"11286","DOI":"10.1038\/srep11286","article-title":"Fluorogenic Assay\nfor Inhibitors of HIV-1 Protease\nwith Sub-picomolar Affinity","volume":"5","author":"Windsor","year":"2015","journal-title":"Sci. Rep."},{"key":"2026082008091568200_cit34","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0969-2126(00)00537-2","article-title":"Curling of flap tips in HIV-1 protease as a mechanism\nfor substrate entry and tolerance of drug resistance","volume":"8","author":"Scott","year":"2000","journal-title":"Structure"},{"key":"2026082008091568200_cit35","doi-asserted-by":"publisher","first-page":"45121","DOI":"10.1039\/C7RA09691G","article-title":"Structural\ninsights into HIV-1 protease flap opening\nprocesses and key intermediates","volume":"7","author":"Yu","year":"2017","journal-title":"RSC Adv."},{"key":"2026082008091568200_cit36","doi-asserted-by":"publisher","first-page":"15993","DOI":"10.1073\/pnas.1414063111","article-title":"Structural basis\nand distal effects of Gag substrate coevolution in drug resistance\nto HIV-1 protease","volume":"111","author":"O\u0308zen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.\nS. A."},{"key":"2026082008091568200_cit37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1110\/ps.25502","article-title":"Lack of synergy\nfor inhibitors targeting\na multi-drug-resistant HIV-1 protease","volume":"11","author":"King","year":"2002","journal-title":"Protein\nSci."},{"key":"2026082008091568200_cit38","doi-asserted-by":"crossref","first-page":"11939","DOI":"10.1016\/S0021-9258(19)50290-3","article-title":"Regulation\nof autoproteolysis of\nthe HIV-1 and HIV-2 proteases with engineered amino acid substitutions","volume":"268","author":"Rose","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2026082008091568200_cit39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF01028194","article-title":"Large scale purification and refolding\nof HIV-1 protease from Escherichia coli inclusion bodies","volume":"12","author":"Hui","year":"1993","journal-title":"J. Protein Chem."},{"key":"2026082008091568200_cit40","doi-asserted-by":"publisher","first-page":"8062","DOI":"10.1021\/acs.jmedchem.9b00838","article-title":"HIV-1 protease inhibitors\nincorporating stereochemically defined P2\u2019 ligands to optimize\nhydrogen bonding in the substrate envelope","volume":"62","author":"Rusere","year":"2019","journal-title":"J. Med. Chem."},{"key":"2026082008091568200_cit41","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency\nvirus\ntype 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026082008091568200_cit42","doi-asserted-by":"publisher","first-page":"8536","DOI":"10.1128\/JVI.00317-09","article-title":"A strongly\ntransdominant mutation\nin the human immunodeficiency virus type 1 gag gene defines an Achilles\nheel in the virus life cycle","volume":"83","author":"Lee","year":"2009","journal-title":"J. Virol."},{"key":"2026082008091568200_cit43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1021\/acsinfecdis.8b00336","article-title":"Structural Adaptation of Darunavir\nAnalogues against\nPrimary Mutations in HIV-1 Protease","volume":"5","author":"Lockbaum","year":"2019","journal-title":"ACS Infect.\nDis."},{"key":"2026082008091568200_cit44","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"[20] Processing of\nX-ray diffraction data collected in oscillation\nmode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods Enzymol."},{"key":"2026082008091568200_cit45","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"2026082008091568200_cit46","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building\ntools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr.,\nSect. D: Biol. Crystallogr."},{"key":"2026082008091568200_cit47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based\nsystem for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr., Sect. D: Biol. Crystallogr."},{"key":"2026082008091568200_cit48","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1107\/S0907444909029436","article-title":"electronic Ligand\nBuilder and Optimization\nWorkbench (eLBOW): a tool for ligand coordinate and restraint generation","volume":"65","author":"Moriarty","year":"2009","journal-title":"Acta Crystallogr., Sect. D: Biol. Crystallogr."},{"key":"2026082008091568200_cit49","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/355472a0","article-title":"Free R\nvalue: a novel statistical quantity for assessing the accuracy of\ncrystal structures","volume":"355","author":"Bru\u0308nger","year":"1992","journal-title":"Nature"},{"key":"2026082008091568200_cit50","doi-asserted-by":"publisher","first-page":"W375","DOI":"10.1093\/nar\/gkm216","article-title":"MolProbity:\nall-atom contacts and structure validation for proteins and nucleic\nacids","volume":"35","author":"Davis","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"2026082008091568200_cit51","unstructured":"PyMOL\n          \n          The PyMOL Molecular Graphics System, Version 2.3; Schro\u0308dinger, LLC."},{"key":"2026082008091568200_cit52","volume-title":"Schro\u0308dinger Release 2019\u20132","author":"Schro\u0308dinger","year":"2019"},{"key":"2026082008091568200_cit53","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3:\na force field\nproviding broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"2026082008091568200_cit54","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1128\/JVI.02531-09","article-title":"Evaluating\nthe substrate-envelope hypothesis: structural analysis of novel HIV-1\nprotease inhibitors designed to be robust against drug resistance","volume":"84","author":"Nalam","year":"2010","journal-title":"J. Virol."},{"key":"2026082008091568200_cit55","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1021\/acs.jctc.8b00097","article-title":"Hydration\nstructure and dynamics of inhibitor-bound HIV-1 protease","volume":"14","author":"Leidner","year":"2018","journal-title":"J. Chem. Theory Comput."},{"key":"2026082008091568200_cit56","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1021\/acschembio.9b00370","article-title":"Picomolar to micromolar: elucidating\nthe role of distal mutations in HIV-1 protease in conferring drug\nresistance","volume":"14","author":"Henes","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"2026082008091568200_cit57","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0022-2836(02)00470-9","article-title":"On the role\nof the\ncrystal environment in determining protein side-chain conformations","volume":"320","author":"Jacobson","year":"2002","journal-title":"J. Mol. Biol."},{"key":"2026082008091568200_cit58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: consistent treatment of\ninternal and surface\nresidues in empirical pKa predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J. Chem. Theory Comput."},{"key":"2026082008091568200_cit59","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/jcc.20292","article-title":"Integrated Modeling\nProgram, Applied Chemical Theory\n(IMPACT)","volume":"26","author":"Banks","year":"2005","journal-title":"J. Comput. Chem."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.0c00529","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/63\/15\/8296\/12973680\/jm0c00529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/63\/15\/8296\/12973680\/jm0c00529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:48:03Z","timestamp":1787230083000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/63\/15\/8296\/1305747\/Structural-Analysis-of-Potent-Hybrid-HIV-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":59,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2020,7,16]]},"published-print":{"date-parts":[[2020,8,13]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00529","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]}}}